

## Post Test, Evaluation, and Credit Application Form

### *Invasive Fungal Infections:*

### *The Impact of Host-, Organism-, and Treatment-Related Factors on Outcomes*

### Webcast on Demand

**Release Date: December 10, 2012    Credit Expiration Date: December 10, 2013**

#### INSTRUCTIONS FOR CREDIT

1. Review the entire CME information including target audience, learning objectives, and disclosures.
2. Review each episode.
3. Print and complete the Post Test, Evaluation, and Credit Application form.
4. Please note that in order to receive credit you must achieve a score of at least 70%.
5. Mail the completed Post Test, Evaluation, and Credit Application Form to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or fax to (908) 235-4222 or email to bhassid@vemcomeded.com.

*Please note: If you have received credit for attending the live symposium by the same name, you are not eligible to apply for credit for this online version.*

*Documentation of credit will be mailed 4-6 weeks of receipt of the completed Form.*

#### CREDIT APPLICATION (Please Print Clearly)

Name and Degree (please write clearly) \_\_\_\_\_

Practice Setting \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Country \_\_\_\_\_ E-mail \_\_\_\_\_

Type of Credit    *AMA PRA Category 1 Credit*™ \_\_\_\_\_    **Other** \_\_\_\_\_

Please indicate the total amount of time you participated in the program: \_\_\_\_\_ hours

**Signature** \_\_\_\_\_    **Date** \_\_\_\_\_

#### POST TEST (Please select the most appropriate answer)

1. Which species accounts for the highest proportion of *Candida* infections?

- C. krusei*     *C. albicans*     *C. glabrata*     *C. parapsilosis*

2. Iron overload is a risk factor for:

- Aspergillosis     Invasive candidiasis     Mucormycosis     Zygomycosis

3. Recent caspofungin exposure is a risk factor for *Candida* infection with reduced caspofungin susceptibility.

- True     False

**POST TEST (cont'd)**

4. The PNA FISH assay can identify infections caused by:  
 *C. albicans*       *C. parapsilosis*       *C. tropicalis*       All of the above

5. The  $\beta$ -D-glucan assay does not detect infections caused by:  
 *Aspergillus*       *Cryptococcus*       Mucorales       *Aspergillus* and Mucorales

6. Which finding from high-resolution CT of the lungs is an early indicator of IFI?  
 Smaller nodules  
 Air crescent  
 Ground glass opacity  
 Halo

7. When using the serum galactomannan assay to detect invasive aspergillosis, which of the following is associated with a false-negative result?  
 Antifungal use  
 Presence of other fungi  
 Use of amoxicillin/clavulanate  
 Solid organ transplantation

8. Therapeutic drug monitoring should be considered to improve the appropriate dosing of:  
 Fluconazole       Voriconazole       Caspofungin       Micafungin

9. The AmBiLoad Trial demonstrated that a higher loading dose of liposomal amphotericin B (10 mg/kg/day) was more effective than and just as safe as a lower loading dose (3 mg/kg/day).  
 True       False

10. Which species of *Candida* is most likely to exhibit reduced susceptibility to the echinocandins?  
 *C. glabrata*       *C. tropicalis*       *C. krusei*       *C. parapsilosis*

<b>LEARNING OBJECTIVES: Please rate if the Learning Objectives were met.</b>	<b>1 Disagree</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5 Agree</b>
Recognize the changing epidemiology of invasive fungal infections					
Assess the latest diagnostic approaches for early detection of IFIs					
Identify at-risk patients to guide antifungal prophylaxis					
Select an appropriate antifungal agent based on evidence-based guideline recommendations and patient factors					

If you answered "Disagree" to any objective, please explain.

<b>FACULTY: Please rate overall faculty effectiveness and subject matter expertise.</b>	<b>1 Fair</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5 Excellent</b>
<b>Pranatharthi H. Chandrasekar, MD</b>					
Teaching Ability					
Knowledge and expertise in the subject					
<b>Richard H. Drew, PharmD, MS, BCPS, FCCP</b>					
Teaching Ability					
Knowledge and expertise in the subject					
<b>Kieren A. Marr, MD</b>					
Teaching Ability					
Knowledge and expertise in the subject					
<b>Comments:</b>					

<b>OVERALL EVALUATION</b>	<b>1 Disagree</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5 Agree</b>
The content was relevant to my practice and educational needs.					
I intend to make changes based on participating in this activity.					
The activity was fair, balanced, and without commercial bias.					
<b>If you feel that the material was NOT presented in a fair and balanced manner, please explain further.</b>					
<b>What do you consider to be the biggest challenges in management of patients with IFIs?</b>					

<b>DO YOU HAVE (1) ANY SUGGESTIONS FOR IMPROVING THIS ACTIVITY or (2) ANY ADDITIONAL COMMENTS?</b>

**PRACTICE APPLICATION AND COMMITMENT TO CHANGE**

	<b>1 Not Important</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5 Very Important</b>
How important to you is a patient-centered approach in management of invasive fungal infections?					

As an accredited provider of continuing education, we are asking our learners to reflect on how they might alter their practices as a result of participating in CME activities. The request below solicits your commitment to change based on what you have learned. We hope that you will find this exercise useful and thank you in advance for participating.

**1. Based on your participation in this activity, do you plan to make any changes in your professional practice?**

Yes       No

**2. Please describe the changes you plan to implement related to:**

*a. Patient-Centered Approaches*

*b. IFIs Treatment Strategies*

*c. System-based Opportunities and Improvement*

**3. What are the barriers you anticipate that may impact implementation of these changes?**